254 related articles for article (PubMed ID: 26290435)
1. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
Stohl W; Merrill JT; Looney RJ; Buyon J; Wallace DJ; Weisman MH; Ginzler EM; Cooke B; Holloway D; Kaliyaperumal A; Kuchimanchi KR; Cheah TC; Rasmussen E; Ferbas J; Belouski SS; Tsuji W; Zack DJ
Arthritis Res Ther; 2015 Aug; 17(1):215. PubMed ID: 26290435
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
3. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
Lenert A; Niewold TB; Lenert P
Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
[TBL] [Abstract][Full Text] [Related]
5. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.
Scheinberg MA; Hislop CM; Martin RS
Expert Opin Biol Ther; 2016; 16(5):723-33. PubMed ID: 27051973
[TBL] [Abstract][Full Text] [Related]
6. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
Petri MA; Martin RS; Scheinberg MA; Furie RA
Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Isenberg DA; Petri M; Kalunian K; Tanaka Y; Urowitz MB; Hoffman RW; Morgan-Cox M; Iikuni N; Silk M; Wallace DJ
Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
Witcher J; Fleischmann R; Chindalore VL; Hansen RJ; Hu L; Radtke D; Voelker J; Gomez E; McColm J
Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus.
Nestorov I; Papasouliotis O; Pena Rossi C; Munafo A
J Pharm Sci; 2010 Jan; 99(1):524-38. PubMed ID: 19743503
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
18. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
Pena-Rossi C; Nasonov E; Stanislav M; Yakusevich V; Ershova O; Lomareva N; Saunders H; Hill J; Nestorov I
Lupus; 2009 May; 18(6):547-55. PubMed ID: 19395457
[TBL] [Abstract][Full Text] [Related]
19. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
20. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]